55
Views
10
CrossRef citations to date
0
Altmetric
Original Articles

Nevirapine or Efavirenz Combined with Two Nucleoside Reverse Transcriptase Inhibitors Compared to HAART: A Meta-Analysis of Randomized Clinical Trials

, &
Pages 113-121 | Published online: 29 Jan 2015

REFERENCES

  • Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.
  • Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349:1294.
  • Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450–454.
  • Sendi PP, Bucher HC, Craig BA, Pfluger D, Battegay M. Estimating AIDS-free survival in a severely immunosup-pressed asymptomatic HIV-infected population in the era of antiretroviral triple combination therapy. Swiss HIV Co-hort Study. J Acquir Immune Defic Syndr Hum RetroviroL 1999;20:376–381.
  • Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in ad-vanced HIV-1 disease. Lancet. 1998;351:543–549.
  • Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725–733.
  • Pocock SJ. Clinical Trials: A Practical Approach. New York: Wiley; 1983.
  • Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta block-ade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335–371.
  • Mantel N, Haenzel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–748.
  • D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996;124:1019–1030.
  • Henry K, Erice A, Tierney C, et al. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. J Acquir Immune Defic Syndr Hum RetroviroL 1998;19:339–349.
  • Montaner JSG, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS trial. JAMA. 1998;279:930–937.
  • Haas D, Seekins D, Cooper R, et al. A phase II, double-blind, placebo-controlled, dose ranging study to assess the antiretroviral activity and safety of efavirenz (EFV, SUSTIVA, DMP 266) in combination with open-label zidovudine with lamivudine at 36 weeks. Presented at: XIII International Conference on AIDS; July 1998; Geneva. Ab-stract 22334.
  • Mayers D, Jemsek J, Eyster E, Tashima K, Thompson M, Ruiz N. A double-blind, placebo-controlled study to assess the safety, tolerability and antiretroviral activity of efavirenz (EFV, Sustiva, DMP 266) in combination with open-label zidovudine and lamivudine in HIV-1 infected patients. Pre-sented at: XIII International Conference on AIDS; 1998; Geneva. Abstract 22340.
  • Floridia M, Bucciardini R, Ricciardulli D, et al. A random-ized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse tran-scriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease. J Acquir Immune Defic Syndr Hum RetroviroL 1999;20:11–19.
  • Albrecht M, Katzenstein D, Bosch R, Liou S, Hammer S. ACTG 364: Virologic efficacy of nelfinavir and/or efavirenz in combination with new nucleoside analogs in nucleoside experienced subjects. Presented at: Sixth Conference on Retroviruses and Opportunistic Infections; 1999; Chicago. Abstract 489.
  • Murphy RL, Katlama C, Johnson V, et al. The Atlantic Study: A randomized, open-label trial comparing two pro-tease inhibitor (PI)-sparing antiretroviral strategies versus a standard P1-containing regimen. 48 weeks data. Presented at: 39th Interscience Conference on Antimicrobial Agents Chemotherapy; 1999; San Francisco. Abstract LB–22.
  • Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865–1873.
  • Podzamczer D, Ferrer E, Consiglio E, et al. Preliminary results of a randomized multicenter study comparing Combivir (ZDV/3TC) plus nelfinavir or nevirapine in HIV-infected naive patients (COMBINE study). Presented at: Seventh Conference on Retroviruses and Opportunistic Infections; 2000; San Francisco. Abstract 510.
  • Ruiz L, Negredo E, Domingo P, et al. Clinical, virological and immunological benefit of switching the protease inhibi-tor by nevirapine in HAART-experienced patients suffering lipodystrophy: 36-week follow-up. Presented at: Seventh Conference on Retroviruses and Opportunistic Infections; 2000; San Francisco. Abstract 206.
  • Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults. Updated recommendations of the Inter-national AIDS Society - USA Panel. JAMA. 2000;283:381–390.
  • Moyle GJ. Efavirenz: Shifting the HAART paradigm in adult HIV-1 infection. Exp Opin Invest Drugs. 1999;8:473–486.
  • Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995;122:573–579.
  • Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency vi-rus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis. 1998;177:40–47.
  • Eron JJ Jr. The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: A review of North American (NUCA 3001) and European (NUCB 3001) trials. AIDS. 1996;10:S11–519.
  • Staszewski S, Hill AM, Bartlett J, et al. Reduction in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: A meta-analysis of controlled trials. AIDS. 1997;11:477–483.
  • Brun-Vezinet F, Boucher C, Loveday C, et al. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee. Lancet. 1997;350:983–990.
  • Moss AR, Bacchetti P. Natural history of HIV infection. AIDS. 1989;3:55.
  • Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trial Group. Ann Intern Med. 1990;112:727–737.
  • HIV Trialists Collaborative Group. Zidovudine, didanosine and zalcitabine in the treatment of HIV infection: Meta-analyses of the randomised evidence. Lancet. 1999;353:2014–2025.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.